Chris Shibutani
Stock Analyst at Goldman Sachs
(3.40)
# 952
Out of 5,124 analysts
95
Total ratings
54%
Success rate
17.26%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $56.15 | +78.09% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $12.29 | -75.59% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $13.96 | +7.45% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $34.91 | -8.34% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $106.62 | +28.49% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $21.01 | +57.07% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $485.36 | -37.78% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $44.65 | +14.22% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $239.99 | -35.41% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $13.98 | -71.39% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $8.21 | +143.61% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,058.18 | -31.68% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $13.49 | +92.74% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $141.20 | +8.36% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $223.43 | -22.57% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $36.81 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $61.99 | +11.31% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $21.80 | -40.37% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $97.49 | -76.41% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $13.96 | +258.17% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $79.59 | -34.67% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $27.22 | +120.43% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $10.64 | +69.17% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $12.51 | +35.89% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.32 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.94 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $56.15
Upside: +78.09%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $12.29
Upside: -75.59%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $13.96
Upside: +7.45%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $34.91
Upside: -8.34%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $106.62
Upside: +28.49%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $21.01
Upside: +57.07%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $485.36
Upside: -37.78%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $44.65
Upside: +14.22%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $239.99
Upside: -35.41%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $13.98
Upside: -71.39%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $8.21
Upside: +143.61%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,058.18
Upside: -31.68%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $13.49
Upside: +92.74%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $141.20
Upside: +8.36%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $223.43
Upside: -22.57%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $36.81
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $61.99
Upside: +11.31%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $21.80
Upside: -40.37%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $97.49
Upside: -76.41%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $13.96
Upside: +258.17%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $79.59
Upside: -34.67%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $27.22
Upside: +120.43%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $10.64
Upside: +69.17%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $12.51
Upside: +35.89%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $7.32
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.94
Upside: -